SOMAÍ Pharmaceuticals has made a bold move into the Australian market, introducing an innovative portfolio of cannabis-based products. This strategic expansion is not just about entering a new market; it’s about bringing about a revolution in patient care and product availability.
A Vision for Consistency and Innovation
At the heart of SOMA’s mission is a commitment to patient interest. The company’s investment of A$1.6 million speaks volumes about its long-term vision for Australia. By ensuring a consistent supply of innovative cannabis formats, SOMAÍ is set to become a household name in healthcare circles.
A Partnership for the Future
The collaboration with the U.S. award-winning Airo Brand is a testament to SOMA’s dedication to quality and consumer focus. This partnership is expected to usher in a new era of medical cannabis products adhering to the highest safety and quality standards.
Setting Standards with EU-GMP Quality
SOMA’s state-of-the-art facility in Portugal and its adherence to EU-GMP standards ensure that the products reaching Australian shores are nothing short of excellent. The anticipated product line includes inhalation oils and a range of vaporizers that promise to set a new benchmark in the industry.
SOMA’s Impact on the Global Cannabis Market
The global cannabis market is witnessing a significant transformation, and SOMA Pharmaceuticals is at the forefront of this change. With its eyes set on the future, SOMAÍ is not just entering markets; it’s setting the pace for others to follow.
A Global Reach with Local Sensibilities
Understanding the local market while maintaining global quality standards is what sets SOMA apart. The company’s approach to tailoring products to meet the specific needs of the Australian market is a game-changer.
A Financial Boost for Ambitious Plans
With a recent capital raise of €5 million, SOMAÍ is gearing up for an ambitious expansion. This financial boost is directed towards its own sales and distribution, particularly in Germany and Australia, indicating a strong focus on these markets.